Peptide-based therapy in portal hypertension

Area of Science:

• Gastroenterology and Hepatology
• Pharmacology

Background:

• Portal hypertension is a serious complication of cirrhosis.
• Acute variceal hemorrhage and hepatorenal syndrome are critical manifestations.
• Vasoactive peptides are key therapeutic agents for these conditions.

Purpose of the Study:

• To review the current literature on gastrointestinal peptides for managing portal hypertension.
• To summarize the efficacy and application of specific vasoactive peptides.

Main Methods:

• Literature review of studies on vasoactive peptide use.
• Analysis of clinical trial data and outcomes.
• Synthesis of current understanding and recent developments.

Main Results:

• Somatostatin, octreotide, vasopressin, and terlipressin are primary treatments.
• Early peptide administration correlates with better outcomes in variceal hemorrhage and hepatorenal syndrome.
• Octreotide is currently available in the US; terlipressin shows promise.

Conclusions:

• Vasoactive peptides are essential in managing acute variceal bleeding and hepatorenal syndrome.
• Ongoing research may expand the role of peptides like terlipressin.
• Optimizing peptide therapy can improve patient prognosis in portal hypertension.